Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Notable: Multi-target TMS for Schizophrenia Negative Symptoms Start date pushed from Oct 1, 2026 to Dec 1, 2026 Shanghai Mental Health CenterNot applicable NCT07559084
  2. Notable: Therapeutically Alternatives In Ventilator-Induced Diaphragm Dysfunction Critically Ill Patients Primary completion date changed from estimate of Oct 1, 2024 to Sep 1, 2025 South Valley UniversityNot applicable NCT06515600
  3. Notable: Honest Open Proud for Psychotic and Bipolar Disorder in Norway Primary completion date changed from estimate of Dec 31, 2024 to Oct 30, 2026 Oslo University HospitalNot applicable NCT06384755
  4. Notable: Sprint Interval Training on Field Hockey Players Primary completion date changed from estimate of Jul 15, 2024 to Aug 25, 2026 Riphah International UniversityNot applicable NCT06502626
  5. Notable: Underlying Mechanisms of Group Natural Psychotherapy for Anxiety Symptoms Enrollment increased: 55 → 120 participants Beijing HuiLongGuan HospitalNot applicable NCT07731568
  6. Notable: Pain, Central Sensitization, and Misophonia in Lipedema Start date pushed from Sep 28, 2026 to Nov 19, 2026 Gaziantep City HospitalNot specified NCT07849634
  7. Notable: Application of the J-PET Scanner Prototype Study completion date changed from estimate of Oct 30, 2025 to Jun 7, 2026 Jagiellonian UniversityNot specified NCT06242119
  8. Notable: Decode the Environment Variation of Targeted Aldosterone Inducer and siLencer Start date pushed from Oct 10, 2026 to Dec 10, 2026 DejthidaNathaphongNot applicable NCT07748975
  9. Notable: Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence Results posted: Nov 20, 2026 UNICANCERNot applicable NCT03127995
  10. Notable: Roybal Via Habit Formation Start date pushed from Oct 1, 2026 to Jan 15, 2027 Louisiana State University and A&M CollegeNot applicable NCT07848178
  11. Notable: Risk Factors and Outcomes of Hepatitis A in Children Start date pushed from Sep 26, 2026 to Nov 26, 2026 Assiut UniversityNot specified NCT07848321
  12. Notable: Disease Outcomes and Toxicities · Gastrointestinal and Sarcomatous Malignancies Enrollment increased: 180 → 450 participants UNC Lineberger Comprehensive Cancer CenterNot specified NCT05743426
  13. Notable: Targeted Therapy to Increase RAI Uptake in Metastatic DTC Primary completion moved earlier from Feb 1, 2031 to Jul 2027 Children's Hospital of PhiladelphiaNot specified NCT05024929
  14. Notable: Mobile App, AI Chatbot, and Printed Materials to Improve Parents' Dental Trauma Knowledge and Emergency Decisions Eligibility criteria changed Lincoln University CollegeNot applicable NCT07927062
  15. Notable: Paraffin Wax on Joint Contractures Start date pushed from Oct 2026 to Feb 1, 2027 Centre hospitalier de l'Université de Montréal (CHUM)Not applicable NCT07837687
  16. Notable: Empowered Relief for Severe Pain After Cesarean Delivery During the Inpatient Period Start date pushed from Oct 5, 2026 to Nov 30, 2026 Stanford UniversityNot applicable NCT07832240
  17. Notable: Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder Enrollment reduced: 180 → 120 participants New York State Psychiatric InstitutePhase 2/3 NCT05011266
  18. Notable: Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) Enrollment reduced: 1944 → 1117 participants Instituto de Investigación Marqués de ValdecillaPhase 4 NCT07611747
  19. Notable: Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer Enrollment reduced: 1760 → 1150 participants Isabelle HenskensNot applicable NCT07146295
  20. Notable: Effects and Safety of CT-P51 and Keytruda · Previously Untreated Metastatic Lung Cancer Primary endpoint(s) modified CelltrionPhase 3 NCT06939595
  21. Notable: Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis Results posted: Nov 19, 2026 Bausch Health Americas, Inc.Phase 3 NCT05071716
  22. Notable: Outcomes of Efgartigimod PH20 SC · New-onset Generalized Myasthenia Gravis (gMG) Primary endpoint(s) modified argenxPhase 4 NCT06909214
  23. Notable: SOA101 · Advanced Solid Tumors Primary endpoint(s) modified Shine-On Biomedical Co., Ltd.Phase 1/2 NCT07055594
  24. Notable: NEROFE, a Novel Hormone-Peptide · Advanced MDS and AML Primary completion pushed from Jun 30, 2025 to Dec 31, 2027 Immune System Key LtdPhase 1 NCT04365179
  25. Notable: External Electrical Stimulation for Male Incontinence Results posted: Nov 19, 2026 Elidah, Inc.Not applicable NCT06620419